CHD7 and cancer: How deregulating CHD7 and MLL3/4 may impact cancer progression is not entirely clear, though recent studies linking enhancer and super-enhancer deregulation to cancer formation suggest that the deregulation of enhancers upon mutation of Kismet/CHD7 and the Trr/MLL3/4 complex could drive aberrant proliferation (Herz et al., 2014, Hnisz et al., 2013).